Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Capricor Therapeutics (NASDAQ: CAPR) will release first quarter 2026 financial results after market close on May 12, 2026 and will host a conference call and webcast the same day at 4:30 p.m. ET.

Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) will release first quarter 2026 financial results after market close on May 12, 2026 and will host a conference call and webcast the same day at 4:30 p.m. ET. A replay will be available in the Investors section of capricor.com.

The company described its lead candidate Deramiocel (late-stage development for Duchenne muscular dystrophy) and its StealthX exosome platform in preclinical work.

Argus May 5 session

-1.61% close to close Open Argus

Details

News Market Reaction – CAPR

On May 5, the first trading day after this news, CAPR closed 1.61% below the previous close.

Data tracked by StockTitan Argus for the May 5 session.

Market Context

This announcement sets the timeline for Q1 2026 results and a corporate update, maintaining communic...

Analysis

This announcement sets the timeline for Q1 2026 results and a corporate update, maintaining communication around Deramiocel’s late-stage development in Duchenne muscular dystrophy and the StealthX exosome platform. Historically, Capricor’s news flow has centered on HOPE-3 data, the BLA under FDA review, and its commercialization agreement with Nippon Shinyaku. Investors may monitor the upcoming call for updates on regulatory progress, commercialization planning, cash runway, and any intentions regarding use of its existing shelf registration.

Key Figures

Earnings call date: May 12, 2026 Earnings call time: 4:30 p.m. ET Quarter end date: March 31, 2026

Earnings call date

May 12, 2026

Q1 2026 financial results release and corporate update

Earnings call time

4:30 p.m. ET

Conference call and webcast start time on May 12, 2026

Quarter end date

March 31, 2026

First quarter 2026 period to be reported

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Phase 3 data update

   24h Move

   -0.9%

   HOPE-3 Phase 3 results showed meaningful functional benefit and BLA under review.

2. Mar 12

   Earnings and update

   24h Move

   -8.7%

   Q4/FY 2025 results with positive HOPE-3 data and cash of $318.1M through 2027.

3. Mar 12

   Conference data

   24h Move

   -0.5%

   Additional HOPE-3 data at MDA 2026 showing functional and cardiac benefits in DMD.

4. Mar 10

   Regulatory update

   24h Move

   +9.0%

   FDA lifted CRL and set new BLA PDUFA date of August 22, 2026 for Deramiocel.

5. Mar 09

   Earnings date notice

   24h Move

   +9.8%

   Announcement of date and time for Q4/FY 2025 results and corporate update call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

allogeneic, cardiac-derived cell therapy, Duchenne muscular dystrophy, exosome-based therapeutics, +2 more

6 terms

allogeneic medical

"Deramiocel, an allogeneic cardiac-derived cell therapy that is currently..."

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

cardiac-derived cell therapy medical

"Deramiocel, an allogeneic cardiac-derived cell therapy that is currently..."

A cardiac-derived cell therapy uses living cells taken from heart tissue and grown or processed to treat damaged heart muscle; think of it as sending specialized repair crews made from heart material to patch or stimulate healing in a failing heart. Investors care because these therapies aim to change long-term patient outcomes rather than just manage symptoms, which can create durable demand, high development costs, regulatory risk, and potentially large market value if proven safe and effective.

Duchenne muscular dystrophy medical

"development for the treatment of Duchenne muscular dystrophy (DMD)."

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

exosome-based therapeutics medical

"developing transformative cell and exosome-based therapeutics for the treatment..."

Therapies that use exosomes — tiny, natural packets cells send to communicate — to deliver therapeutic molecules or signals to other cells. Think of them as a biological mailing service that can carry instructions or repair tools to specific tissues; for investors they represent a potential new class of targeted medicines with advantages in precision and safety, but they also carry development, manufacturing and regulatory risks common to early-stage biotech.

oligonucleotides medical

"targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics..."

Short strands of DNA or RNA designed to bind specific genetic sequences, oligonucleotides act like targeted messages that can turn genes on or off, block harmful proteins, or help detect disease. For investors, they matter because they represent a class of therapeutic and diagnostic products with potential for highly specific treatments, large market value, and distinct development, manufacturing and regulatory risks that can drive big gains or setbacks depending on clinical success and approval.

forward-looking statements regulatory

"Cautionary Note Regarding Forward-Looking Statements Statements in this press release..."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET –

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.

Title:	Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast
Date:	Tuesday, May 12, 2026
Time:	4:30 p.m. ET
Call Details:	Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 60968 Participants may dial in using the numbers above and ask to be joined to the call, or use the Call Me™ link for instant telephone access to the event.
Webcast:	Click Here

A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to applicable regulatory approvals. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich
KCSA Strategic Communications
ckasunich@kcsa.com
212.896.1241

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Capricor (NASDAQ: CAPR) report Q1 2026 financial results and hold the conference call?

Capricor will report Q1 2026 results after market close on May 12, 2026 and host a conference call and webcast at 4:30 p.m. ET. According to the company, the event includes dial-in and webcast access and a post-event replay on capricor.com.

How can investors join the Capricor May 12, 2026 conference call for CAPR?

Investors may join via the provided toll-free or international numbers or use the Call Me™ link for instant access. According to the company, the conference ID is 60968 and a live webcast will be available on capricor.com.

Where will Capricor (CAPR) post the webcast replay of the May 12, 2026 event?

A replay will be posted in the Investors section of capricor.com shortly after the live event concludes. According to the company, the replay will remain accessible on the corporate website for on-demand viewing by investors.

What pipeline updates did Capricor (CAPR) highlight ahead of the Q1 2026 report?

Capricor highlighted Deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for DMD, and its StealthX exosome platform in preclinical work. According to the company, these programs focus on cardiac/skeletal muscle preservation and targeted delivery technologies.

Who can I contact for investor or media questions about Capricor's May 12, 2026 release?

Media inquiries can be directed to Caitlin Kasunich at KCSA Strategic Communications; investor/company questions to AJ Bergmann, CFO. According to the company, email and phone contacts are provided for both media and corporate communications.